Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery and Advance Clinical Trials
Alphabet-backed Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital, with participation from MGX, Temasek, and the UK Sovereign AI Fund. The Google DeepMind spin-off will use the investment to scale its AI drug design engine and expects to begin clinical trials by late 2026, marking a shift from its earlier 2025 target.